ClinicalTrialStartPulse / report
Shanghai Hengrui Pharmaceutical Co., Ltd.: Phase 3 study in Systemic Treatment-naïve Pancreatic Cancer (825 participants)
Shanghai Hengrui Pharmaceutical Co., Ltd.: Phase 3 study in Systemic Treatment-naïve Pancreatic Cancer (825 participants). Its enrollment of 825 is top-decile (93rd percentile of 8,570 records). Dated 7 days ago, it is inside the fresh trigger window. Score 100/100. As of 2026-11-03, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 825 · 93th percentile of 8,570 ClinicalTrialStartPulse records · 10.3x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer |
| NCT ID | NCT07900789 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Systemic Treatment-naïve Pancreatic Cancer |
| Intervention types | drug |
| Target enrollment | 825 |
| Site countries | China |
| Posted | 2026-10-28 |
| Planned start | 2026-10 |
| Event | Newly registered study |
| Event date | 2026-10-28 |
| enrollment percentile | 93th of 8,570 (median 80, 10.3x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Shanghai Hengrui Pharmaceutical Co., Ltd.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Shanghai Hengrui Pharmaceutical Co. + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-28
- Data refreshed: 2026-11-03
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Tue, 03 Nov 2026 05:11:05 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Shanghai Hengrui Pharmaceutical Co., Ltd. and 6,377 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,377
- Shanghai Hengrui Pharmaceutical Co., Ltd.'s enrollment: 93rd percentile of 8,570 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,275,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
100 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 825 participants planned.
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Shanghai Hengrui Pharmaceutical Co., Ltd.?
Shanghai Hengrui Pharmaceutical Co., Ltd. registered a Phase 3 study (NCT07900789) in Systemic Treatment-naïve Pancreatic Cancer targeting 825 participants, posted 2026-10-28.
How does Shanghai Hengrui Pharmaceutical Co., Ltd. compare to other ClinicalTrialStartPulse records?
This is a top-decile record: its enrollment of 825 is 10.3x the median of 80 across 8,570 records. It is fresh: dated 7 days ago, inside the window where early outreach matters most. Its Score of 100/100 puts it among the stronger signals in this feed.
Shanghai Hengrui Pharmaceutical Co., Ltd. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Shanghai Hengrui Pharmaceutical Co., Ltd. | NONUS | 825 | 93rd | 2026-10-28 |
| Merck Sharp & Dohme LLC | NONUS | 564 | 90th | 2026-11-02 |
| AstraZeneca | NONUS | 1,200 | 95th | 2026-11-02 |
| Keymed Biosciences Co.Ltd | NONUS | 320 | 84th | 2026-11-02 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Shanghai Hengrui Pharmaceutical Co., Ltd. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Shanghai Hengrui Pharmaceutical Co., Ltd. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.